Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors - PubMed (original) (raw)
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors
A David McCollum et al. Am J Clin Oncol. 2004 Oct.
Abstract
Background: The combination of streptozocin and doxorubicin has been considered the standard palliative chemotherapy regimen in patients with advanced pancreatic endocrine tumors (PETs). However, a recent review failed to confirm high antitumor activity in patients with advanced PETs.
Methods: We retrospectively reviewed the records of 16 consecutive patients who received streptozocin and doxorubicin for advanced PETs at Dana Farber/Partners Cancer Care institutions. Baseline patient characteristics, radiographic response to therapy, treatment-related toxicity, progression-free and overall survival were analyzed.
Results: One patient demonstrated an objective partial response to therapy (objective response rate [ORR], 6%; 95% confidence interval [CI], 0-18%). Six patients achieved stable disease (38%; 95% CI, 14-62%) and 9 patients demonstrated disease progression on initial restaging (56%; 95% CI, 33-77%). The median progression-free survival and overall survival were 3.9 months (95% CI, 2.8-8.8) and 20.2 months (95% CI, 9.7-37.4), respectively.
Conclusions: In this retrospective cohort, the combination of streptozocin and doxorubicin failed to demonstrate substantial antitumor activity in patients with advanced PET. Our findings underscore the need for new therapeutic options in this patient population.
Comment in
- Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.
Vilar E, Tabernero J, Casado E, Macarulla T, Ramos FJ, Martinelli E, Saura C. Vilar E, et al. Am J Clin Oncol. 2005 Aug;28(4):424. doi: 10.1097/01.coc.0000162426.79311.a5. Am J Clin Oncol. 2005. PMID: 16062087 No abstract available.
Similar articles
- Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Rogers JE, Lam M, Halperin DM, Dagohoy CG, Yao JC, Dasari A. Rogers JE, et al. Neuroendocrinology. 2022;112(1):34-42. doi: 10.1159/000514339. Epub 2021 Jan 12. Neuroendocrinology. 2022. PMID: 33434908 Free PMC article. - The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?
Delaunoit T, Ducreux M, Boige V, Dromain C, Sabourin JC, Duvillard P, Schlumberger M, de Baere T, Rougier P, Ruffie P, Elias D, Lasser P, Baudin E. Delaunoit T, et al. Eur J Cancer. 2004 Mar;40(4):515-20. doi: 10.1016/j.ejca.2003.09.035. Eur J Cancer. 2004. PMID: 14962717 - [Chemotherapy for advanced pancreatic carcinoma].
Yokoyama T, Shimada Y. Yokoyama T, et al. Gan To Kagaku Ryoho. 1992 Dec;19(14):2338-43. Gan To Kagaku Ryoho. 1992. PMID: 1463339 Review. Japanese. - Chemotherapy in the treatment of neuroendocrine malignant tumors.
Rougier P, Mitry E. Rougier P, et al. Digestion. 2000;62 Suppl 1:73-8. doi: 10.1159/000051859. Digestion. 2000. PMID: 10940691 Review.
Cited by
- Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R. Lombard-Bohas C, et al. Pancreas. 2015 Mar;44(2):181-9. doi: 10.1097/MPA.0000000000000262. Pancreas. 2015. PMID: 25479584 Free PMC article. Clinical Trial. - Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.
Oberstein PE, Saif MW. Oberstein PE, et al. Clin Med Insights Oncol. 2012;6:41-51. doi: 10.4137/CMO.S7319. Epub 2012 Jan 4. Clin Med Insights Oncol. 2012. PMID: 22253554 Free PMC article. - Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors.
Ferrarotto R, Testa L, Riechelmann RP, Sahade M, Siqueira LT, Costa FP, Hoff PM. Ferrarotto R, et al. Rare Tumors. 2013 Sep 24;5(3):e35. doi: 10.4081/rt.2013.e35. eCollection 2013. Rare Tumors. 2013. PMID: 24179647 Free PMC article. - Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors.
Wiedmann MW, Mössner J. Wiedmann MW, et al. Clin Med Insights Oncol. 2012;6:381-93. doi: 10.4137/CMO.S7350. Epub 2012 Nov 20. Clin Med Insights Oncol. 2012. PMID: 23226079 Free PMC article. - An Unusual Cause for Sister Mary Joseph's Nodule: A Case Report.
Aljehani Y. Aljehani Y. Oman Med J. 2014 Nov;29(6):458-60. doi: 10.5001/omj.2014.119. Oman Med J. 2014. PMID: 25584166 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous